Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTVIREA)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

6 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Befunolol hci	DM8WCXM	Glaucoma/ocular hypertension	9C61	Approved	[2]
Celiprolol hcl	DMD5LBX	Hypertension	BA00-BA04	Approved	[2]
Guanadrel Sulfate	DM6S157	Hypertension	BA00-BA04	Approved	[3]
Ovine corticotropin-releasing hormone	DME0F98	Cushing disease	5A70	Approved	[1]
Oxilofrine	DMRKOS1	Orthostatic hypotension	BA21	Approved	[1]
Terbutyline	DMVPWLZ	Hypertension	BA00-BA04	Approved	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Approved Drug(s)

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dabelotine	DMP2SGN	Cognitive impairment	6D71	Phase 3	[4]
AR08	DM93CTQ	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[5]
------------------------------------------------------------------------------------

1 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID30124346-Compound-60TABLE5	DM3QX0R	Dyskinesia	MB47.4	Patented	[6]
------------------------------------------------------------------------------------

2 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etilefrine	DM67PWD	Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[1]
AIR-Epinephrine	DMGAERX	Allergy	4A80-4A85	Discontinued in Phase 1	[7]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
5	Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
6	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
7	Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.